PL2936151T3 - Sposoby leczenia i/lub ograniczania rozwoju cukrzycy - Google Patents

Sposoby leczenia i/lub ograniczania rozwoju cukrzycy

Info

Publication number
PL2936151T3
PL2936151T3 PL13811451T PL13811451T PL2936151T3 PL 2936151 T3 PL2936151 T3 PL 2936151T3 PL 13811451 T PL13811451 T PL 13811451T PL 13811451 T PL13811451 T PL 13811451T PL 2936151 T3 PL2936151 T3 PL 2936151T3
Authority
PL
Poland
Prior art keywords
diabetes
treating
methods
limiting development
development
Prior art date
Application number
PL13811451T
Other languages
English (en)
Inventor
Per Olof Berggren
Shao-Nian YANG
Original Assignee
Biocrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocrine Ab filed Critical Biocrine Ab
Publication of PL2936151T3 publication Critical patent/PL2936151T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507Pancreatic cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL13811451T 2012-12-18 2013-12-17 Sposoby leczenia i/lub ograniczania rozwoju cukrzycy PL2936151T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738835P 2012-12-18 2012-12-18
EP13811451.7A EP2936151B1 (en) 2012-12-18 2013-12-17 Methods for treating and/or limiting development of diabetes
PCT/EP2013/076917 WO2014095875A1 (en) 2012-12-18 2013-12-17 Methods for treating and/or limiting development of diabetes

Publications (1)

Publication Number Publication Date
PL2936151T3 true PL2936151T3 (pl) 2018-11-30

Family

ID=49876594

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13811451T PL2936151T3 (pl) 2012-12-18 2013-12-17 Sposoby leczenia i/lub ograniczania rozwoju cukrzycy

Country Status (10)

Country Link
US (1) US9068971B2 (pl)
EP (1) EP2936151B1 (pl)
JP (1) JP6322209B2 (pl)
KR (1) KR102141898B1 (pl)
CN (1) CN105051534B (pl)
DK (1) DK2936151T3 (pl)
ES (1) ES2689922T3 (pl)
HK (1) HK1214355A1 (pl)
PL (1) PL2936151T3 (pl)
WO (1) WO2014095875A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3256118A1 (en) 2015-02-09 2017-12-20 BioCrine AB Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
CA2996064C (en) * 2015-08-18 2024-02-13 Novation Pharmaceuticals Inc. Benzopyran derivatives and uses thereof
EP3383869B1 (en) 2015-11-30 2023-06-28 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
WO2017095724A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
DE202017007491U1 (de) * 2016-12-02 2022-01-07 Sophion Bioscience A/S Dichtungsverstärker
CN113967210A (zh) * 2020-07-24 2022-01-25 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
JP2002080499A (ja) * 2000-09-01 2002-03-19 Suntory Ltd カルシウムチャンネル阻害作用を有する新規ペプチド
EP1562605A4 (en) 2002-10-08 2006-07-12 Massachusetts Inst Technology COMPOUNDS FOR MODULATING CHOLESTER INTRANSPORT
ATE409046T1 (de) * 2003-03-12 2008-10-15 Rappaport Family Inst For Res Zusammensetzungen und verfahren zur diagnose und behandlung einer entzündung
PL1623228T3 (pl) * 2003-04-29 2013-04-30 Biocrine Ab APOCIII i leczenie oraz diagnozowanie cukrzycy
CA2622911C (en) * 2005-09-16 2016-12-06 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
WO2009128734A1 (en) * 2008-04-18 2009-10-22 Vialactia Biosciences (Nz) Limited Marker assisted identification of mammals for desired phenotypic trait
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes

Also Published As

Publication number Publication date
KR20150096676A (ko) 2015-08-25
EP2936151A1 (en) 2015-10-28
JP6322209B2 (ja) 2018-05-09
CN105051534B (zh) 2017-08-18
US20140170113A1 (en) 2014-06-19
US9068971B2 (en) 2015-06-30
CN105051534A (zh) 2015-11-11
JP2016510210A (ja) 2016-04-07
HK1214355A1 (zh) 2016-07-22
WO2014095875A1 (en) 2014-06-26
ES2689922T3 (es) 2018-11-16
EP2936151B1 (en) 2018-07-18
KR102141898B1 (ko) 2020-08-06
DK2936151T3 (en) 2018-08-27

Similar Documents

Publication Publication Date Title
EP2675459A4 (en) COMPOUNDS AND METHODS FOR TREATING DIABETES
HK1251796A1 (zh) 治療糖尿病的方法和組合物
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
EP2887805A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
HK1204450A1 (en) Methods of treating celiac disease
HK1209633A1 (en) Compositions and methods for treating diabetes
EP2874647A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT
HK1200348A1 (en) Methods and materials for treatment of pompes disease
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HK1214355A1 (zh) 用於治療和/或限制糖尿病發展的方法
GB201217296D0 (en) Method of treatment and/or prevention
EP2888370A4 (en) DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES
EP2836804A4 (en) DEVICE AND METHOD FOR DETERMINING SAFE TANNING TIME
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
EP2804614A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND / OR ADIPOSITAS
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
HK1210077A1 (en) Methods of treating or preventing respiratory conditions
HK1206791A1 (en) Means and methods for response prediction of hepatitis b treatment
HK1212999A1 (zh) 用於治療和/或限制糖尿病的發展的方法
ZA201408065B (en) Compositions and methods for the treatment of diabetes
PL2864417T3 (pl) Polimer i sposób zastosowania
HK1202819A1 (en) Treatment of type i and type ii diabetes i ii
HK1223034A1 (zh) 用於治療 型糖尿病的方法和養生方案
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment